-+ 0.00%
-+ 0.00%
-+ 0.00%

GENMAB: CLARIFY OVERALL SURVIVAL (OS) WAS SOLE U.S. PRIMARY ENDPOINT IN PHASE 3 EPCORE(®) DLBCL-1 TRIAL AND WAS NOT MET

Reuters·07/23/2026 20:00:00

Please log in to view news